Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
AUSTIN, Texas, June 13, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced the company recently began clinical studies for the Gastrointestinal (GI) Assay on the VERIGENE® II System, its new sample to answer benchtop molecular diagnostic system in development. The VERIGENE System enables clinicians to rapidly identify the pathogens responsible for some of the... Read more